Krishnan Suma sold $122K of KRYS
Krishnan Suma (President, R&D) sold 400 shares of Krystal Biotech, Inc. (KRYS) at $304.89 ($0.12M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This disclosure updates the record of insider activity but does not introduce new operational/clinical/financial information.
Market read
Traders may monitor insider activity, but the pre-arranged nature typically limits fundamental interpretation.
What to watch
10b5-1 plans can be scheduled regardless of fundamentals; the sale size ($122K) may be too small to change valuation expectations.
Background
SEC Form 4 reports an insider’s transaction in the issuer’s own stock; Rule 10b5-1 indicates the trade was pre-planned.
Ticker impact
Krystal Biotech insider Krishnan Suma (President, R&D; 10% owner) sold $121,957 of KRYS shares under a 10b5-1 plan.
Limited near-term impact; any reaction is likely sentiment-driven and small.
The filing is a routine insider transaction with stated 10b5-1 pre-arranged plan, reducing interpretive value versus discretionary sales.
Market effects
No direct sector read-through; this is company-specific insider disclosure.
None.
None.
Counterpoint
If investors treat any insider selling as bearish despite 10b5-1, KRYS could see short-lived negative sentiment.
Key entities
- issuerKrystal Biotech, Inc.
Subject of the Form 4 insider sale by President, R&D (10% owner).
- insiderKrishnan Suma
President, R&D; officer/director/10% owner who sold 400 shares on 2026-06-04.
